In this pooled analysis, comparisons of DPP-4i therapy and other treatment for type 2 diabetes (with 10 included trials) were performed, providing evidence that DPP-4i treatment was not significantly associated with changing leptin levels in participants from different regions in comparison with placebo. This evidence concerns the gene LEP and type 2 diabetes mellitus.